As we mark the Fourth of July here in the U.S.A., we thought this would be a great time to explore the idea of freedom as it relates to our dependence on diabetes apparatus.
Admit it: As free as we can sometimes feel about the flexibility modern diabetes technology provides, our devices also serve as a constant reminder of our illness, shadowing us wherever we go. Most of us, at one time or another, have…
Lee Ann Thill is a beloved diabetes blogger at The Butter Compartment. I remember when she appeared on the scene a few years ago, and told us what she did for a living. All I could think at the time was, “what the heck?” Sounds like I am not alone. A big hug goes out to Lee Ann for breaking new ground — and of course for sharing her thoughts with us today at the…
Read more »
Al Mann, CEO of MannKind Corp., is something of a legend in his own time. He not only founded MiniMed, acquired by Medtronic, but also four other successful medical companies. He’s a billionaire, with his own Biomedical Engineering Institute at the University of Southern California (USC), so we can assume that he’s not just championing the new inhalable insulin product Technosphere (brand name Afresa) as some kind of pipe dream or get-rich-quick scheme.
The guy…
There are a lot of things going on at the troubled Food and Drug Administration right now that could have a profound impact on the future of diabetes care, but most of us patients never hear about them. And that’s a damn shame. Because we stand at a crossroads.
You may or may not be aware that the Obama Administration is about to appoint a new FDA Commissioner. The politics and personal leanings of this…
Dr. Rubin, a renowned endocrinologist and author based in San Francisco, CA, has some strong opinions about the lack of ethics within drug companies, as evidenced by his last guest post here on conflict of interest. Today, in Part 2, he offers some tips on protecting yourself from exploitation.
A Guest Post by Alan L. Rubin, M. D.
In the first of two articles, I wrote about my increasing discouragement with the drug industry, particularly…